🇺🇸 FDA
Pipeline program

ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%

ARQ-151-313

Phase 3 small_molecule completed

Quick answer

ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% for Atopic Dermatitis Eczema is a Phase 3 program (small_molecule) at Arcutis Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Arcutis Biotherapeutics
Indication
Atopic Dermatitis Eczema
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials